Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Azelon Pharmaceuticals
Age
45–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal Females Age ≥ 45 years.
Weight \> 45 kg and \< 90 kg
Normal nasal examination at baseline.
Low bone mass at lumbar spine, total hip or femoral neck (BMD T-score of ≤ - 1.5 or lower) or a recent (within 5 years of baseline) history of fragility fracture (excluding fractures of hands, feet, face and/or skull) and a T-score of -1.0 or lower at lumbar spine, total hip or femoral neck
You may not be if
Serious Medical Condition
History of diseases which affect bone metabolism other than postmenopausal osteoporosis such as Paget's disease, any secondary causes of osteoporosis, hypoparathyroidism, or hyperparathyroidism
Have a history of cancer within the past 5 years, except for basal cell carcinoma
Have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney stones or pre-existing hypercalciuria;
Have used any of the mostly commonly prescribed osteoporosis medications within 3 months of starting the investigational product, or for more than 1 month at any time within 6 months prior to starting investigational product
Clareo Health | Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
